|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
Light chain monoclonal gammopathy of undetermined significance (MGUS) has a very low probability of progressing to symptomatic multiple myeloma, according to the results of a new study by researchers in Germany.
The German researchers found that, with a median follow-up time of 11.5 years, none of the 75 people in their study who had light chain MGUS saw their MGUS progress to symptomatic multiple myeloma, amyloidosis, or a related disease.
In fact, in more than half of the 31 cases …
A team of European researchers has published results of a major clinical trial investigating the efficacy and safety of Pomalyst (pomalidomide, Imnovid) and dexamethasone in multiple myeloma patients who have had many prior therapies.
Results of the trial, known as the STRATUS (MM-010) study, have previously been presented at several major medical meetings. This is the first time, however, that the results have been summarized in a journal article.
The new efficacy and safety results are in line …
How has your week been, myeloma world?
Summer definitely is here at Myeloma Morning Headquarters. We had temperatures yesterday and today that rival those normally seen in early August.
We're not exactly sure how we feel about this development.
As for myeloma-related news, we have a lot of ground to cover.
We have one new myeloma research study that we summarize at length. It's about a difficult subject, namely, the impact of early relapse on the overall survival of multiple …
Good morning, myeloma world.
We hope you had a pleasant weekend and that your new week is off to a good start.
The big news today is that Darzalex (daratumumab) has been approved in Europe as a new treatment for multiple myeloma. We will be publishing a separate news article on the approval, which was announced a few hours ago. In the meantime, you can find information about the approval in this press release from Genmab, the …
Good morning, myeloma world.
Since the last edition of Myeloma Morning, abstracts for two important upcoming medical meetings have been made public: the American Society of Clinical Oncology (ASCO) annual meeting, which will take place June 3 through June 7 in Chicago, and the European Hematology Association (EHA) annual congress, which is scheduled for June 9 through June 12 in Copenhagen, Denmark.
The publication of the abstracts and the meetings themselves mean that there is going to be a lot …
Hello, myeloma world.
We hope your week has gotten off to a great start.
We're looking forward to reviewing three new myeloma-related research studies with you today.
The first study we summarize in today's report focuses on the survival of older blood cancer patients, including (of course) older multiple myeloma patients.
The second study presents the results of the CHAMPION-1 clinical trial, which tested once weekly Kyprolis in combination with dexamethasone in relapsed multiple myeloma patients.
The final study we …
It's good to see you again, myeloma world.
We got tied up the past couple days with, among other things, coverage of the Empliciti approval in Europe. But we're glad to be back and we have two new research studies that we'd like to discuss with you.
First, we take a look at an Israeli study that does a deep dive into the t(11;14) chromosomal abnormality in newly diagnosed multiple myeloma patients. The focus of this particular deep dive …
